A national registry for acute coronary syndromes will improve patient care and clinical results
Acute coronary syndromes (ACS) represent a substantial burden of morbidity and mortality within Australia.1 Modern treatment of these syndromes requires efficient risk stratification, timely angiography and revascularisation, and use of proven secondary prevention therapies.2-4 With a robust evidence base, it is a reasonable societal expectation that care be applied as completely as possible, to optimise recovery and secondary prevention. Clinical performance measures for ACS care have a central role in facilitating the translation of the evidence base into improved clinical outcomes.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
We thank Colleen Bichel, Neville Board, Carrie Toohey, Karen Uhlmann and Jinty Wilson for contributions to and review of our article.
Derek Chew has served on advisory boards for AstraZeneca and Eli Lilly and has received consultancy fees for Flinders University from Abbott Vascular and payment for lectures from AstraZeneca. David Brieger has served on advisory boards for and has received payment for lectures from AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Sanofi, and has received research grants to the University of Sydney from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Sanofi and Merck.